Drug Database
Back to search

Switzerland· 16397003

Prostigmin 12,5 mg/5 mL, Injektionslösung

A neostigmine product, registered in Switzerland by MEDA Pharmaceuticals Switzerland GmbH and dispensed under Swissmedic category B. The same ATC class is registered in 10 of our 19 countries.

Cat B (Swissmedic)ATC N07AA01

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · CHPublic registernormalisedProstigmin 12,5 mg/5 mL, Injektionslö…ATCN07AA01REGISTER NO.16397003PACKS LISTED0CHECKEDJune 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ProstigminAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Neostigmine is registered in 10 of 19 countries.

Countries holding a registration under ATC N07AA01 (neostigmine), each read from that country’s own register.

  • This record: Switzerland
  • 6 of them publish a price we can compare per daily dose
Search neostigmine products by name

Neostigmine · ATC N07AA01

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Finlandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Manufacturer
MEDA Pharmaceuticals Switzerland GmbH
Country
Switzerland (CH)
ATC code
N07AA01
ATC class
Neostigmine
Defined daily dose
60 mg, O
Swissmedic category
B
Reimbursed
No
Last checked
June 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

68 interactions on record for neostigmine.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check neostigmine against other medicinesHow interaction checks work

Neostigmine · interactions on record

68 records

  • 6 severe
  • 62 moderate

Most severe, free to view

  • SiponimodL04AA42severe
  • SiponimodL04AE03severe
  • BupropionN06AX12severe
  • BupropionN07BA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under N07AA01

Neostigmine, as other registers publish it.

All neostigmine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f0415a15-9c18-45a1-af22-3f8fc0f961bb
GET /v1/drugs/f0415a15-9c18-45a1-af22-3f8fc0f961bb?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "swissmedic_auth",
  "heilmittelcode": "Synthetika"
}
API referenceMCP serverPlans

See everything about neostigmine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console